Abstract:The Medical Journal of Australia ISSN: 0025729X 15 May 2006 184 10 487-488 ©The Medical Journal o f Aus tr a l ia 2006 www.mja.com.au Editorials n line with its Vision 2020 initiative, the World Health Organization adopted a resolution to eliminate blinding trachoma by 2020. To achieve this goal, WHO recommends the SAFE strategy (Surgery, Antibiotics, Facial cleanliness and Environmental improvement) for countries implementing trachoma control programs. Australia is the only developed country of the 57 trachoma endemic countries listed by WHO. Trachoma was endemic and a significant cause of blindness in many parts of the Western world, including Australia, ntil the early 1900s. As housing, hygiene and living conditions improved, trachoma disappeared from most parts of Australia. However, these improvements are yet to occur in remote Aboriginal populations in Australia, where trachoma is still endemic. Why is Australia the only developed country with endemic trachoma? Firstly, the socioeconomic determinants of trachoma (ie, poverty and overcrowded living conditions) are highly prevalent among Aboriginal people living in remote areas. Secondly, Australia’s trachoma control efforts have been patchy and inconsistent since the National Trachoma and Eye Health Program finished in 1978. In the absence of a national approach, some trachoma-endemic states or areas have prioritised trachoma control and have implemented programs based on the 1993 WHO trachoma control guidelines, while others have not. Furthermore, while all current programs include periodic trachoma screening and antibiotic treatment, very few include the “S”, “F” and “E” components. Thirdly, epidemiological data on trachoma, an essential element of any control program, are difficult to obtain and interpret because each trachoma control program has its own data collection system, and data from different regions and states are not collated. Trachoma is not a nationally notifiable disease. Thus, despite availability of a highly effective one-dose treatment (azithromycin) provided free through remote Indigenous health clinics and regional population health units since 1998, trachoma transmission continues. Recent molecular epidemiological research from the Northern Territory showed different Chlamydia trachomatis strains in coastal compared with inland communities, indicating that trachoma transmission may occur more within communities or within groups of neighbouring communities rather than between far-flung, distant communities. In contrast, a similar Western Australian study showed that most WA trachoma strains were of the Ba Apache type, which circulated in both coastal and central communities across the length and breadth of WA and was identical to one of the NT strains.5 This finding is consistent with anecdotal reports of high levels of mobility of Indigenous people within and between regions, and suggests that the effectiveness of trachoma control activities may be improved by enhanced inter-regional coordination (eg, conducting trachoma screening and treatment at the same time in all affected areas). The publication of the Guidelines for the public health management of trachoma in Australia, which were developed by the Department of Health and Ageing and the Communicable Diseases Network of Australia (CDNA), and the Australian Government’s allocation of $920 000 towards trachoma control over the next 3 years represent a long-awaited national approach to controlling this preventable disease. The states and ter ri to rie s w i l l rece ive $470 000 of this new funding, to train health workers to implement consistent trachoma screening and control measures. The remaining $450 000 will be used to establish a national trachoma surveillance unit to enable consistent data collection on trachoma. The CDNA’s trachoma steering group, which has representatives from states and territories where trachoma is endemic, will provide expert advice regarding trachoma surveillance and control. The guidelines cover trachoma screening, control and data collection (Box). They recommend that trachoma control, including data collection and reporting, should be the responsibility of, and coordinated by, government-run regional population health units, working in collaboration with primary health care services and Aboriginal community representatives. The guidelines stress the importance of implementing all four components of the SAFE strategy. In accordance with one of the resolutions of the 2003 Global Scientific Meeting on Trachoma, the guidelines recommend single-dose azithromycin for all children and all adult household contacts of affected people when Better late than never: a national approach to trachoma control

The Expression of Interleukin-15 in Peripheral Blood Mononuclear Cells of Patients with Systemic Lupus Erythematosus

Dysregulated T Cell Activation and Aberrant Cytokine Expression Profile in Systemic Lupus Erythematosus.

Aberrant T Cell Subsets and Cytokines Expression Profile in Systemic Lupus Erythematosus.

Decreased Plasma IL‐22 Levels and Correlations with IL‐22‐Producing T Helper Cells in Patients with New‐Onset Systemic Lupus Erythematosus

Levels of Soluble Interleukin-2 Receptor and Clinical Significance in Patients with Systemic Lupus Erythematosus

[Clinical Significance of CD4+CD25+ T Cells in Peripheral Blood of Patients in Systemic Lupus Erythematosus].

Better late than never: a national approach to trachoma control

Abnormal Expression of Cd43 in Patients with Systemic Lupus Erythematosus and Its Clinical Significance

Expression of interleukin-17 in peripheral blood of patients with systemic lupus erythematosus and its correlation with disease activity

Elevated Serum Interleukin-35 Is Associated With Disease Activity In Patients With Systemic Lupus Erythematosus

Serum Interleukin-2 Receptor Α As a Clinical Biomarker in Patients with Systemic Lupus Erythematosus

Effect of Interleukin-15 on CD11b, CD54, and CD62L Expression on Natural Killer Cell and Natural Killer T-Like Cells in Systemic Lupus Erythematosus

Increased Urinary Interleukin 22 Binding Protein Levels Correlate with Lupus Nephritis Activity

Principles of treatment and update of recommendations for the management of haemophilia and congenital bleeding disorders in Italy.

Th22, but not Th17 Might be a Good Index to Predict the Tissue Involvement of Systemic Lupus Erythematosus

Correlation of plasma interleukin-18 concentration and severity of renal involvement and disease activity in systemic lupus erythematosus

Potential biomarkers for diagnosis and assessment of disease activity in systemic lupus erythematosus

Expression of P-selectin in peripheral blood of patients with systemic lupus erythematosus and its clinical significance

Elevated Expression Of Transmembrane Il-15 In Immune Cells Correlates With The Development Of Murine Lupus: A Potential Target For Immunotherapy Against Sle

Correlation between circulating interleukin-18 level and systemic lupus erythematosus: a meta-analysis

High Interleukin 21 Levels in Patients with Systemic Lupus Erythematosus: Association with Clinical Variables and rs2221903 Polymorphism